LIVE: Senate Hearing on Restoring America’s Edge in Generic Drug Manufacturing

Live News Network
1.4K followers
45 Video Views·Sep 23, 2026
The Senate Special Committee on Aging’s full committee holds a hearing on “Leveling the Playing Field: Restoring America’s Edge in Generic Drug Manufacturing” at 3:30 p.m. ET on Sept. 23.
Witnesses:
Kurt Orlofski, CEO, PAI Pharma
Christine Baeder, president, Apotex USA and LATAM
Mihir Torsekar, senior economist, Coalition for a Prosperous America
AI Generated·May contain errors
The U.S. Senate Special Committee on Aging will now come to order.
Over this past year, this committee has sounded the alarm on the dangers of America's over-reliance
on foreign adversaries for our medicine. We've heard from patient advocates,
researchers, and manufacturers about their concerns and how it's putting our families
at risk every single day. One thing is clear, there's an urgent need to address
our dependence on communist China and India for drugs. And that starts with making safe
medicines here in America. This week, the Trump administration announced a great step
towards further investing in American drug manufacturers. I'm glad to note the Trump
administration is taking action. Now we need to see more American companies getting contracts
with federal agencies to make drugs here in America. That's the test. We need to see urgency
in both the executive and legislative branches to make changes that end America's dependence
on communist China for prescription drugs. I'm proud that the Clear Labels Act, which I'm leading
with Ranking Member Gillibrand, passed a health committee almost unanimously in July. I expected
to get a vote on this before the end of the year. That would not have happened but for Senator
Gillibrand's hard work on it also. We must pass this bill and make sure Americans know where their
drugs are made. Here's why I'm so fired up about getting this done. America now makes just 27% of
things that we put into our body. In 2002, that figure was 72%. We've almost completely lost our
ability to make generic drugs in this country. This was no accident. This is the result of
decades of Washington's failure to combat communist China's control of what's in your
medicine cabinet and the drugs we put in our bodies. Manufacturers in communist China and
India are cheating. We see them falsify records as we saw with Ramboxy. President fake
conditions the FDA inspectors in pre-announced inspections. They cut corners on quality
in medicines that people's health and lives depend on. Just recently, the Chinese equivalent
FDA leadership got convicted for taking bribes to approve ineffective drugs. Communist China
does not play fair and they couldn't care less about our safety and well-being. We cannot take
chances by relying on them for medicine. We also know that foreign manufacturers get to the market
fastest by undercutting American manufacturers. They're complying with the FDA's approval
inspection processes. That can be fixed. The federal government should not reward that.
The FDA needs to treat this as a both a national security and safety issue. Congress needs to give
the FDA the tools it needs to support domestic manufacturing and the highest quality manufacturing
here in the USA. The federal government should support policies that bring drug manufacturing
back without patients and health systems have to face higher prices and they can't. One example is
the first to file a reform proposal in the FDA's fiscal year 2027 budget request. Market-based
solutions like this would give American manufacturers the first chance to become
an exclusive manufacturer of drugs going off patent by giving them a one-month head start.
By the way, what do you think China is doing? This proposal would have a huge impact,
give American manufacturers a chance to compete on an even playing field and sending a much-needed
signal to industry to invest in manufacturing here long term. Other ideas such as CMS proposed rule
to reimburse more for drugs made in America are a great step in the right direction. The time for
action is now. We can't let issues like permitting and government bureaucracy stop manufacturing from
coming back to this country. The government needs to take an all-hands-on-deck approach to cut red
tape so we can make medicines here in America and save and protect American lives. American
manufacturers can compete on quality and cost and I'm committed to working with Ranking Member
Gillibrand and the Trump administration to make changes happen so they have a fair shot of
bringing manufacturing back to our great country. Now I'll turn it over to Ranking Member Gillibrand
for her opening statement. Thank you Chairman Scott for calling today's hearing and thank you
for our witnesses. This committee has dedicated an enormous amount of time and resources to
studying solutions on how we can strengthen our pharmaceutical supply chain. The Aging Committee
has held eight hearings on this topic and even authored a major policy report on securing the
foreign generic pharmaceutical supply chain and today we have come to our final hearing on how
the United States can restore our edge in generic drug manufacturing for the 919th Congress.
We've studied risks to the supply chain, country of origin labeling reforms, and how the United
States must keep its dominance in the biotech race against China. We've learned that one of
the key aspects of strengthening our supply chain is to reform the underlying market incentives that
incentivize this race to the bottom. I'm so proud of the bipartisan legislation that originated from
this committee, our Clear Labels Act, to the Bipartisan Pharmaceutical Investment Oversight
Accountability Act. The resilience of America's pharmaceuticals have been a topic of interest for
Congress even before COVID shined a light on our fragility of our supply chain. Drug shortages,
drug recalls are issues that are top of mind for Americans when they happen but are quickly
forgotten. Thanks to the work of this committee, Congress has finally had time to focus on the
issues that impact our patients and constituents. I look forward to continuing this bipartisan
momentum that the Aging Committee has created to get this done, and I look forward to continuing
my work with Chairman Scott and our partners in the private sector on how we can address these
pressing issues. Thank you, Ranking Member Gillibrand. I'd like to welcome our witness panel
of industry and trade experts who are here today to talk about how we can bring drug manufacturing
back to the country and stop relying on communist China and India for our medicine. First, I'd like
to introduce Kurt Olofsky. He is the CEO of PAI Pharma, an American manufacturer based in South
Carolina. He boasts over 20 years of experience in the genetic drug industry. I welcome him to share
his expertise with the committee about how we make drugs here in America. Thank you for being here
today. Please begin your testimony. Good afternoon, Chairman Scott, Ranking Member Gillibrand and members
of the committee. It really is an honor to be here today and to be invited to testify before
the committee. Each year, PAI manufactures over 100 million doses of life-saving oral liquid and
sterile medications, proving that a domestic drug manufacturer can actually thrive and support the
U.S. supply chain. Our proposal is really three prongs to strengthen domestic drug supply. One,
let Americans see it. Two, make the FDA prioritize it, the it being the domestic drug manufacturer,
and give Americans a choice. First, let Americans see it. In the U.S., nearly 90 percent of
prescriptions are filled with affordable generic medicines, and FDA reports that nearly 70 percent
of generic drugs are manufactured outside the U.S. Yet, in 2026, hard to believe, Americans still
cannot tell where the drugs are made. PAI supports the Clear Labels Act. Patients should be able to
see where the finished medicine and API is manufactured, period. FDA has this information
today but does not make it available to consumers. Listing only the domestic distributor's U.S. address
can lead a patient to believe the medication is made in the U.S. when we know nearly 70 percent
of the time it is not. Second, make the FDA prioritize it. We need more of our finished
drugs, APIs, and KSMs domestically manufactured. COVID, as one example, showed us why. In 2020,
India restricted exports of 13 APIs and 13 formulations and later restricted even additional
medications as COVID went on. Those actions were likely not politically motivated or aimed
specifically at the U.S. However, when an emergency occurs, governments understandably put their own
citizens first. At FDA today, there is little differentiation between a domestic and a foreign
manufacturing entity. Application fees, review timelines, and compliance policies are similar.
For example, a foreign finished dose facility pays only $15,000 more in annual FDA fees
than a domestic facility. That distinction should be more meaningful. FDA reviewer time is finite,
as we know. FDA has taken a positive first step with its domestic ANDA prioritization pilot,
a program intended to provide faster reviews to generic companies that manufacture and test in
the United States. This incentive for new products needs to also be applied to existing products.
An application to move finished dose manufacturing or API sourcing to the U.S.
should have the fastest review time possible. An application for the first or second domestic
source of a critical medicine should not wait behind the 15th or 20th foreign application
in an already crowded drug market. Third, give Americans the choice. Drug wholesalers
and retail chains effectively fill millions of prescriptions daily. They alone decide whether to
source a product from a domestic or foreign manufacturer. As of today, there is no requirement
or financial incentive for them to source an American-made drug. In many cases, a domestic
manufactured drug is not even available in pharmacies today, in U.S. pharmacies today.
We must start by getting domestic manufactured drugs on our pharmacies shelves. The payment
system also for prescriptions should align with and incentivize domestic manufactured drugs first.
One Medicare Part D analysis found roughly $15 of drug payment slash reimbursement per prescription
for the drug donepezil, for example, while the manufacturer receives only about $5 of the 15.
This tells us there is economic value available in the system. So before we start asking a senior
to pay more for an American-made generic, we should ask whether more of the dollars already
in the system can reach the manufacturer making the medication domestically. And finally, generic
pharmaceuticals are currently exempt from the formal Section 232 tariffs, but the administration
has directed commerce to reassess that within a year. While tariffs need safeguards for shortages
and medically vulnerable products, for most finished products today, they would be an effective
and required push for action now. And where tariff revenue is generated, Congress should consider
reinvesting some of the revenue in domestic plant modernization and purchasing incentives
for US-made generics. So our proposal, pretty simple, let Americans see it, make the FDA prioritize it,
and give Americans the choice. These actions will strengthen domestic, the domestic drug
supply starting today. Thank you, and I look forward to your questions. First, congratulations
on your business. Thanks for the testimony. Thank you. I'll turn it over to Ranking Member
Gillibrand for our next witness. Thank you, Mr. Chairman. I want to move to Christine Bader.
Ms. Bader is the President of Apotex, Apotex USA and LATAM, where she leads efforts to expand
the company's commercial footprint in US hospital and specialty care markets and broaden its portfolio
of treatment options. Previously, Ms. Bader was Senior Vice President and Chief Operations Officer
for US Generics and Biosimilars at Teva Pharmaceuticals. She serves on the Board for
the Association for Accessible Medicines and served as Chair of the Board in 2023. You may begin.
Good afternoon, Chairman Scott, Ranking Member Gillibrand, and the members of the committee.
Thank you for the opportunity to appear before you today. My name is Christine Bader. I am the
President of Apotex Corp. We're based in Western Florida. Apotex is proud to supply high-quality,
life-saving medicines to millions of patients in the United States and around the world.
Apotex supplies over 130 product families to American patients every day. Apotex strongly
supports this committee's important work to secure a resilient domestic supply chain for
generic medicines for American families. As this committee has correctly observed,
generic manufacturers are increasingly reliant on unstable and unsustainable foreign supply chains.
As a pharmaceutical executive during COVID, I approached every day making high-stakes decisions
to transfer products that were produced overseas to service the American patients that needed them.
We have a responsibility to learn from COVID. Apotex applauds the committee's work to tackle
this problem head-on, including providing patients with the information they deserve to know
on where their medicines and the ingredients they are composed of come from. Apotex strongly
supports the Clear Labels Act and looks forward to working with Congress to see it signed into law.
Mr. Chairman, in order to implement the solutions that will most effectively secure a resilient
domestic supply chain, we need to look at how we got here. The factors that caused generics
to leave the United States all flow from one simple reality. For generics, the math doesn't
work. Let me say that again. The math does not work. Generics exist in a race-to-the-bottom
environment where North American manufacturers cannot compete with lower-cost overseas
manufacturers who rely on government subsidies. Apotex has personally lived this reality.
We were a leading North American manufacturer of penicillin, perhaps the most essential of
all essential medicines. Because of unsustainable market conditions, we had to demolish that plant
last year. As an industry, we cannot keep tearing down buildings and exiting markets.
We must incentivize and empower the generic industry and reverse the economics.
Fortunately, we already have a powerful tool that Congress can leverage.
It's the central part of what built the generic industry, the Hatch-Waxman Grand Bargain.
The tool is the 180-Day Exclusivity Incentive. Let me be clear. The 180-Day Exclusivity is the
most important incentive that drives every decision we make. The 180-Day Exclusivity
rewards the first generic to trailblaze and take on the expense of challenging brand patents.
Once it was so important that the generic manufacturers would camp outside of the FDA,
like fans do for a college basketball game in hope of getting that first slot,
recalibration of this extraordinarily important incentive is necessary. In recent years,
the value of the 180-Day Exclusivity for brand drugs known as New Chemical Entities, or NCEs,
has eroded. This is a big deal for patients, as the drugs are the most critical breakthrough
drugs on the market, the exact ones that are desperately needed at lower cost alternatives.
But under the current system, the math once again does not work. Let me explain. In 2003,
FDA decided to grant shared exclusivity to the generics who submit on the same day for NCEs.
Instead of crowning a winner, the 180-Day prize is now split amongst the crowd.
As an example, Eliquis, a blockbuster drug subject to Medicare price negotiation,
has 25 first applicants. Stripping the value of the incentive in this way has a predictable
consequence. Prices drop to unsustainable levels, manufacturers flee overseas, and we're right back
where we started. 180-Day Exclusivity is the ideal place to start repairing our broken system.
As with any incentive, the details matter. I want to make three points clear today. First,
we need a strong incentive for APIs to return to the United States. Hard stop. It is not acceptable
for us to merely take Chinese inputs, finish them in the United States, and deem on-shoring a
success. We need to target API, which is the root cause of the issue. Second, on-shoring will take
time, as you recognize. Apotex is supportive of different phased approaches. That said,
our immediate priority is on-shoring and friend-shoring of API. Third, the current NCE
submission rules should stay in place. Even when there is no domestic manufacturer,
certainty is required for an incentive to work. Apotex applauds the committee's efforts to tackle
the critical issues facing the generic supply chain and protect American families. It is not
too late to right this ship. Apotex stands ready to partner with Congress. Thank you again,
and I welcome your questions. Thanks for your testimony. Sometimes you sit and think,
why can't this? This stuff is not that hard. If I was running one of these federal agencies,
you do it today. You make the changes now. Next, I'd like to introduce our final witness
here, Tor Sakkar. He's a senior economist with the Coalition for a Prosperous America,
and is here today to share his over 15 years' experience in the international trade sector
and the intersection of national security and trade. His work has been featured in major
publications. I appreciate him being here to discuss the critically important issue
of securing our supply chains and bringing generic drug manufacturing back to our country.
Thanks for being here. Please begin your testimony. Chairman Scott, Ranking Member Gillibrand,
and members of the committee, thank you for the opportunity to testify today.
My name is Mihir Tor Sakkar, senior economist at the Coalition for a Prosperous America,
and I'm presenting CPA's research on generic drug manufacturing, led by my colleague Andrew
Reschenberg, including our report, The Hollowing Out of America's Medicine Cabinet. The generic
plants America has lost over the past decade held every FDA approval and every permit they needed.
They closed because the price of the medicines they made fell below the cost of making them
reliably. Regulatory reform is necessary, but on its own it produces faster approvals for plants
that can't stay open. The United States now makes 27 percent of the medicine it consumes,
down from 72 percent in 2002. Two categories of medicine show what that means. The first
is liquid acetaminophen and ibuprofen, the medicines for patients who cannot swallow a
tablet. Imports have doubled since early 2024, and since January of last year, India has supplied
83 percent of them, and China has supplied 99 percent of the imported ibuprofen ingredient.
The second category is 11 tablets that tens of millions of Americans take every morning
for blood pressure, heart failure, diabetes, seizures. The United States imports 78 percent
of its solid oral generics. India makes 61 percent of what we dispense, and American plants only make
22 percent. China subsidized the chemistry, India subsidized the finishing. At home, a handful of
buying groups control about 90 percent of generic purchasing, and award contracts at the lowest
price. Amlodipine, which now sells for a penny and a half, now sells for a penny and a half a tablet.
At those prices, plants in West Virginia, Maryland, and Alabama all closed over the past decade,
rendered unprofitable by American generic prices on a playing field tilted toward India. Nearly
half of the shortages that began this year involve a drug with a single supplier, so one plant's
problem becomes a national shortage. There are 227 active shortages today, and the average one
lasts more than five years. Oversight is tilted as well. Domestic plants are inspected without
warning, while foreign plants received advance notice nearly 90 percent of the time, and many
went five years or more with no FDA visit. Generics made in India are associated with a 50 for 4
percent more serious adverse events than the same drugs made here. Reliable domestic supply is cheap.
Only 36 cents of every retail generic dollar reaches the manufacturer. If making a generic in
America costs about 40 percent more on average than in India, the premium for reshoring is only
six and a half cents on the retail dollar. In CPA's case study, reshoring pays for itself if it cuts
the annual risk of a major shortage by about one percentage point, and roughly 30 billion doses of
FDA-approved generic capacity already sit idle. CPA proposes five reforms. First, fix the FDA
approval process. Make priority review for U.S.-made generics permanent, and let American plants that
use ingredients from trusted MRA sources qualify. Second, apply one inspection standard everywhere.
Foreign plants should face unannounced inspections at domestic frequency, and high-risk imports should
be independently tested. Third, clear the path for new plants. Use the GDUFA reauthorization now
to raise and index the foreign facility surcharge and spend it on inspectors, and put a clock on
permitting for essential medicine facilities. Fourth, pay for reliability. Finalize CMS's domestic
procurement designation, sign multi-year federal contracts, and pass the Pills Act. Then, use
Section 708 of the Defense Production Act to bring the buying alliances that control 90 percent
of generic purchasing to the table under a voluntary agreement. That authority is permanent,
and HHS can use it now. Fifth, fix the market economics. Set the generic tariff as a specific
duty, cents per dose, on imports from high-risk countries with trusted MRA supply at low or zero
rates. A 100 percent tariff on a penny-and-a-half tablet adds a penny-and-a-half, and it moves
nothing. The duty should arrive sooner rather than later, and the contracts should be signed now.
None of this raises costs for seniors at the pharmacy counter. The domestic premium is under
a dollar a prescription, and it falls on the 36 cents of each dollar that reaches the manufacturer.
What reaches seniors is the shortage. Paying for resilience by design costs cents on the dollar.
Paying for it during a shortage costs hospitals hundreds of millions of dollars, and costs older
Americans their medicines. Congress can choose the cheaper options, and it should choose it now.
Thank you. Thank you. Pretty common sense. No, not that hard to do. Okay, Mr. Olofsky, American
manufacturers are being undercut left and right, with foreign manufacturers from communist China
and India cheating at every corner. How can the federal government combat this cheating and
support American manufacturers who do things by the book? We believe that there's clearly a
multi-pronged approach to this, too. Number one is the FDA obviously has to do the work,
and they have to inspect those facilities equally and unannounced, as they do for the U.S. facilities.
That's super important. I think, secondly, though, you can't have a U.S. consumer buy the product if
it isn't on the shelf. It has to be on the shelf. What can the U.S. government do to get
those products on the shelf? We spend a lot of time thinking about that. The government,
through CMS and Medicare and DOD, those purchases are significant. They're meaningful,
but a lot of that goes through the wholesalers. We believe that if the government can begin to
require a certain portion of the purchases come from domestic manufacturers, and even do it over
time, in the first year maybe it's a third, the second year another third, something like that,
where if you want to participate in those programs with the government, you have to source
X amount of it domestically. That's probably the second thing the government can do.
To what my colleague Mahir said, we've seen proposals out there that starts this 5, 10,
15 years in the future. There's no reason it can't start right now. The last thing is,
as I was on the train this morning, I thought to myself, let me see if I can identify every
piece of clothing I'm wearing and where it's manufactured. You know I can. Every piece of
clothing. I'll leave it at that. I won't tell you which ones. I know some are Italy,
there's a few that are American. Yet the medication, I took three pills this morning.
I looked at my bottles this morning. I don't know where they're made. I'm in the industry.
I don't know where they're made. The pharmacists can't tell me that either. We think the most
important thing of all of this is the Clear Labels Act. You have to start with Americans. It's not
just the consumer. If you go up to a pharmacist and ask a pharmacist, where is it made? They don't
know. It's more important, actually, it's just as important that the pharmacist knows that
as the consumer. Then they can start demanding change. I asked the other day at the pharmacy,
there was a generic and it was less than five bucks. I said, if I won the brand, what would
they tell me? $800 and it would take three months for a $5 prescription because we just decimated
all the manufacturers in this country. It's stupidity. Ms. Bader, to break our dependence
on communist China, we need a healthy market for generic drugs. What incentives can the federal
government use to attract manufacturers to make domestic investments? Again, I think the biggest
incentive that you have that isn't in play is the 180-day exclusivity. It moves all the big drugs.
Why aren't they doing that, by the way? Why not? I don't know. I don't know if it's that simple.
I think there's a fear that 180-day exclusivity built the industry. If you look at the generic
industry in the US, I think it is the sole example of something the government got right.
Regulators worked with legislatures, worked with private industries, and we built an enormous
industry. Then we eroded that incentive and the industry moved east. That's what's happened,
and we need to reinvigorate that incentive to bring it back. Why aren't they doing it, though?
China goes out there and says, I'm going to help American manufacturers.
Do they think it's a level playing field in China? Do I think that? No.
Look, I think that we need a legislative way to address that incentive. There's statutory
limitations, and I think that we should move forward with that. But doesn't the FDA have
the ability to make these decisions already? I don't believe that they think they do.
Whether they do or not, I'm not an FDA expert. They make all these other decisions. They're
required to do these inspections. They made the decision to do pre-announced here and not
pre-announced there. That's not statutory. It just makes you mad. If you're going to take these
jobs, and you think their job is the safety for Americans, right, the primary job, couldn't you
say, oh, I can justify this because it's safer for Americans? I would also say to that point
that we need to think about the APIs and the KSMs. Yeah, I agree. If we address just the finished
dose, not that that's a bad thing, but it's not enough. Because from a national security perspective,
if we sort of do something punitive on finished dose manufacturing, there could be a response
on APIs that could start drug shortage that makes me very cautious of that approach. So I think we
need to have a measured approach to make sure we bring the entire supply chain back to French
shores. Do you think if the American public knew where things were made that it'd make a difference?
I'd like to think so, but I don't know. Yeah, there's the test. There's studies, but who knows, right?
Mr. Toscar, over the past two decades, we've seen drug manufacturing go overseas. Much of this can
be blamed on failures here in Washington. What role can the federal government play in addressing
these failures and bringing manufacturing back to the United States? Well, thank you, Mr. Chairman.
I think one of the big things the federal government could do right now is to send out
a strong demand signal. And one of the things you can do is the VA, the DOD, they have immense
purchasing power and they can set contracts up for long-term agreements with manufacturers right
now to make sure... And there's no limitation. They can do that today. There's no law that says
they can't do that. Exactly. And it makes such a difference because when these manufacturers
have a guaranteed market in place, that means that they can take out loans against that from
the bank, things like that, and also utilize capacity. Right now, capacity utilization is
relatively low, and this makes a big difference. But that's only one sliver of the market. You also
have to do things like invoke Section 708 of the DPA, Defense Production Act. HHS can actually
convene all of the three major purchasing alliance groups for the retail pharmacies and the GPOs,
convene them together to get them to agree to set up some sort of like a voluntary agreement
that they are going to purchase more domestically. But I think the biggest thing they can do right
now is to send a strong demand signal to our manufacturers. Thank you, Member Gillibrand.
Thank you, Mr. Chairman. I think you've covered most of my questions, so let me get to one that
you didn't cover. For Mr. Torsakar, in your written testimony, you highlight that roughly
90 percent of FDA foreign inspections in 2023 were pre-announced with up to 12 weeks
advance notice. You highlighted prior testimony that exposed how unannounced inspections identify
manufacturing problems roughly 40 percent of the time, compared to only 5 to 10 for announced
visits. Based on your research, to what extent does this oversight asymmetry function as an
unpriced regulatory subsidy for foreign manufacturers, enabling them to undercut compliant U.S.
producers? And in Pillar 2 of your proposed strategy, you call for making unannounced
inspections. There are concerns that foreign governments could use visa delays or administrative
obstacles to block unannounced visits. How can Congress work to ensure that? And last,
you recommend requiring independent batch testing in certified U.S. laboratories for high-risk
imported drugs paid by the importer fees. How would this requirement be put into practice
without creating supply delays for medications Americans depend on?
Thank you, Ranking Member Gillibrand. So, the big issue that I see here at play is the GDUFA
user fee disparity right now, right? It's only been about $15,000 between the delta between,
like, in India and the United States. That's only about 6 percent of the difference,
and it's been in place for about, you know, since 2012. So, the first thing you can do
is, in the latest updated GDUFA resolutions, I think the plan is to increase that to about
$25,000. $25,000 would go a long way to helping to finance those unannounced inspectors,
pay for visas and things like that. But the importance, you highlighted it just in your
question about the importance of unannounced inspections, because when you give, I mean,
yes, the study that we found for fiscal year 2023, the year for which we have the most
comprehensive year-long data, found that 90 percent of the time, foreign labs were given
up to 12 weeks of notice before an inspector came. And that's important because unannounced
inspections are associated with a 40 percent finding of problems in their labs, whereas if
an inspection is announced prior to arrival, it accounts for only about, like, 5 percent,
5 to 10 percent, you know, problems. So, I think one of the biggest things is getting that
commitment from foreign producers to pay increased user fees and using those fees to finance
additional lab support. Thank you. Ms. Bader, you very effectively testified that the 180-day
exclusivity is the brass ring, but you indicated there were some challenges or
problems with it and need to be updated. Can you be more specific on what you want to update,
how you would update it, how you would improve upon it, and why is this the most effective tool
in shifting generic industry behavior across the entire market compared to direct federal
procurement? So, the incentive that built the industry is a gold standard of an incentive.
The issue is, in 2003, because of the camping out that the manufacturers were doing to get that
person in line, they decided, okay, if everybody's there on day one, it's a tie. So, when you take
the tie and you change it into economic terms, now it's, in the case of Eloquist, which I use,
it's 25 percent of an incentive as opposed to an exclusive expense. So, I think if you
narrow the field, assuming that, you know, domestic manufacturers are going to be a subset of those
25, at least in the beginning, then that should help bring value back to the incentive, as well
as incentivizing the behavior that you're wanting to see, which is on-shoring of the domestic
supply chain. Got it. Thank you. And how does your proposal ensure that the standard of NCE minus one
submission rules remain intact so that the generic applicants are still incentivized to
file at the earliest possible date, even when no domestic manufacturer is initially available?
So, I'm very clear that I believe that the incentive should continue to stand for exclusivity,
and that only once everyone has filed, the FDA can then make a differentiation between
a domestic supplier that will get an additional incentive and then the NCE minus one. So, in that
period of time of transformation, as we're moving from one set of standards to a second set of
standards, we're not creating ambiguity for the FDA, and we're also not creating uncertainty for
the industry, and therefore patients having less access to generic drugs. Mr. Orlovsky,
how should Congress convert the FDA's discretionary pilot into a permanent statutory
priority review framework to give companies the long-term certainty they need to build U.S.
facilities? Specifically, would a tiered system strike the right balance in the interim as the
ramped up? So, number one, make it permanent, right? Number two, they have to put the resources
to it. And so, I don't know exactly how many drugs are in the pilot today, but it's probably
not much more than a handful. So, it needs to be really staffed and prioritized by the FDA
to give priority to it. I think the second thing, though, about it is, and I agree with Christine
on the 180-day exclusivity is the gold standard, and it's very important. But it's future-looking
as well, and I keep coming back to the 70% of our prescriptions today are filled with foreign
manufacturer products. And so, what are we doing about that today? If another pandemic hits six
months from now or a year from now, the first to file on a drug 12 years from now isn't going to
help. So, we need to start bringing that 70% back today. And the FDA can put a very similar program
in place to say, okay, if you file an application to bring a drug back, we'll approve it, assuming
it's approvable, in four months. Right, so shorten the timeline. Shorten the timeline, but also,
you know, I could quote you, I think, I forget which month it was, a couple of months ago, the FDA
approved the 24th version of one drug and the 25th of another. Now, those were resources, reviewer
resources, and my application is behind that. Right, so maybe don't make that the priority.
You have to give FDA guidance on how to review applications. You have to make it very clear,
because if there's anything gray for FDA, that seems to be where they... Well, along the same lines,
how can hospitals, GPOs, and other purchasers be incentivized and supported in choosing to purchase
high-quality drugs from resilient supply chains rather than the cheapest generics on the market?
So there's no incentive today, and in general, the decision isn't even made by the hospital
or even any independent retail pharmacy. It's made by the wholesaler and the chain,
so the chain purchasing. So what really needs to happen there is you need to take some portion of
and shift it. So let's just say a drug is reimbursed $15. Let's just say that's pretty
normal. So higher reimbursement if it's acquired in the United States. Correct, 16 for one and 14
for the other. Good idea. I'd love that. Ms. Bader, do you have an idea, too, on that issue?
No, I mean, I agree. There used to be a differentiation, and what's exciting about
what the administration has done so far and this committee is you're starting to put all the tools
of the government in play, right? So I'm excited about the CMS proposal that incentivizes hospitals
to use domestic supply chains. It's a good proposal, but it doesn't go far enough. None
of the incentive flows back to the manufacturer, and we all know hospitals have their own financial
challenges, so it's doubtful that that will actually flow back to the manufacturer to
incentivize the investment that you need at the manufacturing site. But the concept of using that
type of a strategy is something we haven't seen from government before and very encouraging.
Mr. Torsakar, do you have a thought on that question?
Nothing additional, just I think I can't underscore enough the importance of CMS adding
that additional criteria for reimbursement to reimburse locally or U.S.-produced goods.
To make it a higher reimbursement. Thank you. Thank you, Mr. Chairman.
Thank you. Mr. Olofsky, what does our reliance on communist China India look like for patients,
and what would happen if they cut off the supply and people couldn't get their medications?
So the reliable supply only really matters when you need it, right? And I have a personal
experience with this right in the beginning of COVID. I got COVID, unfortunately, and then I
wound up with pneumonia like two days in. And they gave me an antibiotic, the doctor, and then
another doctor said, oh, no, no, I have experience. The one you need is this one. And I took it, and
I'm alive today. The doctor said, well, if you didn't take that one, you probably would have
as many did at that time. So it becomes a very personal thing, you know, if you get into a
pandemic situation like that, or we're seeing the same thing happen right now with oncology drugs.
You know, it's the sickest of people in their direst of need, and they can't get it. So it's
life or death. It really is. Okay. Mr. Olofsky, what role can our allies in neighboring countries
play in supplying API? I say the first part, what can our allies do to help us on supplying API,
our allies? That's a really good question. You know, I think, to the, to the extent that we
can trust them to supply us in our time of need, the way we supply them, and there's,
I just don't know how you can trust that, given what we've seen. And I'm not speaking ill of our
allies. It's, it's, they're in the same position. They're, they got to represent their country,
and they got to take care of their own people first. We would probably do the same. Yeah.
Ms. Bader, is the federal government doing enough? I don't think the federal government yet has a
holistic plan for APIs, never mind KSFs, right? We need to prioritize the downstream supply chain.
The finished dose supply chain is easier to prioritize, but that doesn't mean it's more
important. Yeah. So, so if you were on the FDA, what are the three things you would do right now?
As, as to encourage API on-choring? Yeah. I don't know if the FDA is the right place to start.
Certainly, they can be a piece of it. They need to be on board. But if you, if there's the only
agency that you could, you're running, the only one you could, you, you only won't get any other
job, and you know what else to talk to, what would you do? Quit? No. No. That's not an answer. You're
not a quitter. No. I, I would, I would figure out what I could do to make the inspection of FDA,
of APIs and KSFs easier using approved API sources. Now, I would support a friend-choring
approach, at least as a transitionary step. Let's work with our allies and get APIs
and the know-how for APIs back into the Western hemisphere so that we can then extrapolate it
and build it. So you make the APIs. How difficult is it to compete with China?
You can't compete with China. It's not a level playing field. So what are they, what are they
doing? They're government subsidized facilities. Is that, is that a violation of the WTO?
I don't know that. It is. So, so they've got subsidies that they just, they drive the price
down so you don't even have a shot. That is always the fear, that as soon as they enter, and look,
that's, I think we're on the precipice. If you look at my testimony, you can see there's charts on
APIs and KSFs. And what you see is that we're more dependent on APIs in India and more dependent for
KSFs in, in China. But if you look at the rate of filings of DMFs, which is the file for the APIs
in China, they're skyrocketing. So if you, if we do nothing and we come back and have this
conversation again in three years, then I'm going to be telling a very different story about our
now increased dependence on APIs in China. So what if China, India stopped all antibiotics
coming to the United States? What would happen? That would be a catastrophic disaster.
Like would, would it cause death? Yes.
And so, so, so of any one drug, antibiotics probably is the most important, right?
Whatever drug you need is the most important, quite frankly. I mean, insulin is important.
Like there's a lot of different categories where we're very overly reliant on foreign sources.
Have you have, um, as does the DOD, um, have, do they take this seriously?
Yeah. The DOD is very proactive, I think.
So they have, they have, um, they have a U.S. sourcing for all their antibiotics.
They have a drive towards U.S. sourcing. I don't know if they've completely been able to find all
of them here. And so, you know, companies that have gotten on antibiotics, you know,
companies that have gotten contracts with DOD to supply it.
Yes. That's good.
That's, that's very positive. Mr. Toscar, um, we've previously talked about the need for federal
government to buy American drugs. Um, so are you seeing that happen?
Um, I, I'm, I'm actually not aware of, of a whole host of, of examples. I mean,
I know that there's isolated instances where, you know, HHS has, um, has signed a contract for,
uh, an API manufacturer, uh, using a continuous dose or continuous process,
which is less environmentally, um, damaging. I think that was back in 2020,
some isolated instances that I'm aware of, but, um, broad scale, not, I'm not as familiar with that.
I think you talked a little bit about the difference between price and value. Can you explain
how, how, how much of like the, how much the end purchaser, how much money actually goes to the
manufacturer? Where's all the money going?
So for every retail dollar that is spent on a generic drug, roughly 64 cents of it goes to
the middleman in the chain. And then 36 cents is going to go to the manufacturer of that 36 cents,
uh, 16 cents is accounted for by the actual manufacturing process. So it's a, it's a small
fraction. Do you think that, uh, foreign drug companies ought to pay a higher FDA user fee?
Oh, absolutely. I mean, we absolutely endorse the, um, the GDUFA, uh, update, uh, for them to pay
up to $25,000. Uh, and that should be indexed to inflation by the way, so that we're not in
a situation where that, you know, allowed to exist into perpetuity. Okay. Thank you.
All right. Well, I think we, we, um, I mean, I, okay. I think, uh, we have Senator Cummings. So
to Mr. Toscar, when FDA negotiates the generic drug user fee, it negotiates with the industry
representative. That is the association for accessible medicines for generic drugs.
Is the FDA negotiating with you as man manufacturers are ultimately negotiating with
Indian companies? I'm sorry. Yeah. I couldn't really answer that right now. Okay. Yeah. All
right. Um, why don't, why don't foreign companies pay a higher FDA user fee?
Unfortunately, I don't have a good answer for that. It's, it seems kind of like common sense
that the fee has been the same since, you know, 2012, right? So hard to say. So if you're running
the FDA, what would you do? Well, one, I think that the first thing I would enforce is, um,
unannounced inspections. Uh, I would also, uh, make sure that we're, um, expediting reviews
for domestically produced drugs. Uh, right now, I mean, I think the, the process works that the,
regardless of the origin of where your drugs are produced, there's no distinction between,
you know, a us made versus a foreign made, um, drug. So I think we have to
prep, uh, prioritize us made manufacturing in the pipeline.
Um, as better, um, you support the clear labels act. Yes. Okay. Um, why would somebody in the
not do that? Because it seems like it's, it's helpful to, and then it's like, if you're an
American company, you're worried about American patients and you were about safety, American
patients didn't worry about our defense industry, all these things. Why wouldn't you support it?
I don't know. I think that the American consumers are becoming increasingly educated,
increasingly focused on their health and increasingly are interested in not only
where their finished goods is made, but also where their APIs are made.
So if they're not supporting it, it seems like they're not as committed to the American consumer.
It seems like they're definitely out of trend with where the American consumer is going.
Senator Kim. Catching my breath here. Thank you, chairman and the ranking member for pulling this
together. And thank you to the three of you, uh, for coming on out here. Uh, Ms. Bader,
I want that to just start with you here. Um, kind of building off of some of what was already
talked about, you know, I've seen a number of different policy, uh, you know, just the policy
incentive proposed to strengthen domestic manufacturing of pharmaceutical products.
Uh, the FDA even proposed offering incentives to the companies that shift production to the U S
to try and build infrastructure. I guess my question to you is what factors should Congress
consider when determining the scale or certain incentives, like whether a product was domestically
manufactured as a finished dosage, uh, if they use domestically manufactured APIs, we're just
trying to get a sense of how to be able to frame that in our minds here. Yeah. So, so for me, I
think, uh, finished dose manufacturing is probably easier to, to fix. Um, it's not something that we
oppose in any way, shape or form, but then we're just going to get to the real choke point, which
is APIs. So we are really focused on incentives that would be more holistic on in getting the
whole supply chain back to the Western hemisphere and focused on, um, not being reliant on any one
nation that may not be supportive of our, our political agendas. Yeah. I mean, I think there's
so broad agreement on that. I mean, it's something that I know you mentioned in your testimony about,
you know, how to be able to address the over-reliance on overseas APIs on the KSMs.
Uh, and so, you know, we're, we're trying to think through how to consider this.
I think the challenge though, is how do we consider the options that will protect our
supply chain resiliency, uh, especially when given some of the most essential medicines and generic
products that are out there. So I guess my, the way I was sort of framing now is, you know, could
you share what considerations we should keep in mind? Um, so we are both achieving a sustainable
domestic manufacturing infrastructure and also preventing the unintended consequences or
vulnerabilities for our supply chain. Like how do we achieve that type of transition without, uh,
putting ourselves at risk? So the generic manufacturing supply chain is extremely
complex, global, and functions on very tight margins. So it's very, um, fragile when it comes
to shocks to the system. So whatever you think about, um, as long as you have time factored in
as a variable that you're very intentional about and clear with the industry about, then I think
you can do anything that you need to do. But what is hard for the industry is if the, if for example,
there's a, a large tariff on a, on a, on an API that comes into the, to the country that may make
that domestic manufacturing not, not, uh, financially reimbursable because those,
those reimbursement rates aren't owned by the same people that own the manufacturing,
right? We have a divergent system. So with time and with the appropriate incentives,
the industry can make the appropriate choices. But if you do it instantaneously,
you can actually cause a negative reaction and create, um, more dependence on, on foreign
producers. Yeah. Mr. Orlovsky, I just wanted to bring you in on this, get your perspective on,
on this in terms of just how do we try to think through that type of transition and resilience
while making sure we're not leaving ourselves vulnerable.
I'm supporting, uh, Ms. Bader's point. It, you know, Rome wasn't built in a day.
We're not going to solve this problem in six months or a year, but you have to start. And
so we think about it in a, in a, in a phased approach, you start with finished goods and
source them domestically. We have a lot of unused capacity in the United States still
to make finished dose products. And yes, we're still going to be relying on APIs
from foreign nations, but at least if you have the dosage form here, it's a start.
Now there's also a difference in quality when it's manufactured in the U S potentially as well.
And we can see that in all the statistics and it's, there's a difference in jobs too,
because if the, if the, if the finished product is made in the United States, the API,
the excipients, that's all tested here as well. So you get that quality check, but also all of
the corresponding jobs, the bottles, the labels, the caps, all the labor, all of that comes back
to the U S as well. So we think start with finished goods, make them here, and then begin
to incentivize, incentivize through, um, through differentiated reimbursement, the domestic
manufactured drugs through the government purchases. Those two things I think really
get the ball rolling. Yeah. Mr. Chairman, can I just have one quick follow up, Ms. Bader back to
you? I'm trying to think through, how do we do this in a way that's going to create sustainable
production to like, how do we know that this is, if we, if we move in this direction, that it's
not just something where again, these companies at a later point, we'll just transfer production
back overseas. I'm trying to think through like, what would actually anchor, what would be that,
that type of anchor that I think, I think Kurt started that with the dedicated programs of
government procurement that are, are based on a differentiation of the entirety of the supply
chain. Um, second to that, the, the challenge with government procurement as the sole instrument is
it's relatively a smaller, it's, it's meaningful. It's not nothing, but it's, you know, five, 10%,
depending on how you look at the number, you need to do something to get the commercial
reimbursement to move. And whatever you can do to have a real conversation with those buyers
and those reimbursement entities to incentivize the same behavior, that will be actually what
finally unlocks it. Thank you. And I yield back.
Thank you, Senator Kim. I want to thank everyone for being here today and participating. Look
forward to continue to work with our members. If any Senators have additional questions for
the witnesses or statements to be added, the hearing record will be open until next Wednesday
at 5 PM. Thanks everybody for being here.
